LNSR$5.80
$6.23
Chart
Performance
Key Stats
AI LNSR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldLENSAR, Inc. shows potential for growth in the medical device sector, particularly with its laser systems for cataract treatment. However, current financial performance indicates significant losses and negative earnings per share, demanding careful consideration. Thematic alignment with healthcare innovation is a positive, but the company's fundamental health requires monitoring.
Thematic
LENSAR operates within the healthcare and medical technology sectors, which benefit from an aging global population and increasing demand for advanced surgical procedures like cataract surgery. The company's focus on innovative laser systems aligns with the trend of technological advancement in healthcare.
Fundamental
LENSAR is currently experiencing significant net losses and negative earnings per share. While revenue has shown some growth, it has not yet translated into profitability. The company's debt level requires careful management, and its cash position needs to be sustained to fund operations.
Technical
The stock price has experienced significant volatility but shows strength in its 1-year performance. Current technical indicators suggest a mixed picture, with some short-term indicators pointing towards caution while longer-term trends remain positive.
| Factor | Score |
|---|---|
| Healthcare Spending Trends | 85 |
| Technological Innovation in Medicine | 80 |
| Medical Device Market Growth | 70 |
| Competitive Landscape | 65 |
| Regulatory Environment (Healthcare) | 75 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 10 |
| Growth | 75 |
| Balance Sheet Health | 25 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Moving Averages | 75 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Short-to-Medium Term Performance
The stock has shown positive performance over the last 1 month (2.27%), 6 months (21.96%), and Year-to-Date (50.17%), indicating recent positive investor sentiment and price momentum.
High Average Trading Volume
The average daily trading volume over the last 30 days (63,590) is significantly higher than the current volume (30,540), which could suggest broader market interest and liquidity, though current volume is moderate.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a significant loss of -$31.40M in 2024 and -$14.38M in 2023. The Earnings Per Share (EPS) figures are also consistently negative, indicating a lack of profitability.
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio is 3.5 TTM and 2.0 for 2024 annual, which, combined with the losses, suggests the current valuation may be high relative to its revenue and profitability.
Calendar
August 2025
7
Next Earnings Date
H: $-0.02
A: $-0.07
L: $-0.13
H: 17.10M
A: 16.55M
L: 16.00M
Profile
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Seasonals
Price Target
15.00 USD
The 39 analysts offering 1 year price forecasts for LNSR have a max estimate of 15.00 and a min estimate of 15.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor and global leader in ophthalmic surgical products, including cataract surgery equipment and intraocular lenses (IOLs).
Weight: 98
Through its Johnson & Johnson Vision segment, a major player in ophthalmic surgery (cataract, refractive) and contact lenses.
Weight: 95
Global leader in ophthalmic lasers, diagnostic equipment, and surgical solutions, including those for cataract and refractive surgery. (ADR for AFX.DE)
Weight: 93
Comprehensive eye health company with a strong presence in ophthalmic surgical devices, pharmaceuticals, and vision care.